SEC Tracker
Get the app

Coherus Oncology CHRS

Coherus Oncology reports Q3 2026 financial results

Coherus Oncology (CHRS) filed an 8-K with the SEC on Nov 9, 2026, 4:20 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. LOQTORZI net revenue of $14.0 million in Q3 2026
  2. 25% increase in Q3 2026 revenue compared to Q3 2025
  3. Right-sizing reduces headcount by ~30%
  4. Core cash burn lowered by $6 million to $7 million quarterly

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Coherus Oncology files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.